Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.8
3.9
Journals
Biomedicines
Special Issues
Molecular Research in Ocular Pathology
share announcement

Molecular Research in Ocular Pathology

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: 28 February 2026 | Viewed by 1331

Special Issue Editors

Dr. Sorin Lucian Bolintineanu

E-Mail Website
Guest Editor
Department of Anatomy and Embryology, “Victor Babes” University of Medicine and Pharmacy, 300041 Timisoara, Romania
Interests: orbital anatomy; retinal vascular diseases; optic nerve morphology; radiology; OCT
Dr. Laura Andreea Ghenciu

E-Mail Website
Guest Editor
1 Department of Functional Sciences, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania 2 Center for Translational Research and Systems Medicine, “Victor Babes” University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania
Interests: OCT; diabetic retinopathy; thyroid eye disease; ocular neuroprotection; clinical ophtalmology

Special Issue Information

Dear Colleagues,

This Special Issue focuses on the molecular mechanisms underlying ocular diseases and their clinical implications. The aim is to bridge the gap between basic molecular research and clinical applications, providing insights into how molecular pathways influence ocular pathophysiology and how they can be targeted for diagnostic, prognostic, and therapeutic strategies.

Ocular diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, thyroid eye disease, uveitis, and corneal dystrophies, often involve complex molecular alterations. These changes involve inflammatory cascades, oxidative stress, angiogenesis, neurodegeneration, and immune dysregulation, which contribute to disease onset and progression. Advances in molecular techniques, such as transcriptomics, proteomics, and metabolomics, have discovered key pathways and biomarkers, offering opportunities for precision medicine in ophthalmology.

For this Special Issue, we welcome original research, reviews, and clinical studies that explore molecular mechanisms, identify novel biomarkers, and investigate cutting-edge therapies for ocular diseases. Additionally, we welcome articles addressing the application of advanced paraclinical investigations and imaging modalities in the diagnosis and management of ocular diseases. Topics of interest include, but are not limited to, the following:

  • Molecular signaling pathways in ocular diseases.
  • The role of biomarkers in early diagnosis and disease monitoring.
  • Insights into gene therapy, cell therapy, and molecular-targeted treatments.
  • The application of imaging technologies in understanding molecular pathology.

This Special Issue seeks to advance the understanding of ocular disease at a molecular level and foster innovative approaches to improving patient outcomes. Researchers and clinicians are encouraged to contribute to this growing field at the intersection of molecular biology and ocular pathology.

Dr. Sorin Lucian Bolintineanu
Dr. Laura Andreea Ghenciu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • molecular pathology
  • ocular diseases
  • biomarkers
  • diabetic retinopathy
  • glaucoma
  • age-related macular degeneration
  • thyroid eye disease
  • inflammatory pathways
  • oxidative stress
  • angiogenesis
  • neurodegeneration
  • gene therapy
  • cell therapy
  • precision medicine
  • ocular imaging

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

18 pages, 707 KiB  
Review
Corneal Endothelial Cell Loss Following Cataract Surgery in Patients with Type 2 Diabetes Mellitus: A Comprehensive Review
by Mădălina-Casiana Salavat, Mihnea Munteanu, Vlad Chercotă, Adina Iuliana Ardelean, Amanda Schuldez, Valentin Dinu and Ovidiu Borugă
Biomedicines 2025, 13(7), 1726; https://doi.org/10.3390/biomedicines13071726 - 15 Jul 2025
Viewed by 400
Abstract
Cataract surgery, while commonly considered a routine, highly effective, and generally low-risk ophthalmic procedure, has been associated with corneal endothelial cell loss (ECL), a phenomenon particularly pronounced in patients with type 2 diabetes mellitus (DM2). This increased susceptibility in diabetic patients is often [...] Read more.
Cataract surgery, while commonly considered a routine, highly effective, and generally low-risk ophthalmic procedure, has been associated with corneal endothelial cell loss (ECL), a phenomenon particularly pronounced in patients with type 2 diabetes mellitus (DM2). This increased susceptibility in diabetic patients is often attributed to pre-existing corneal abnormalities, including compromised structural integrity and reduced endothelial cell density. Additionally, metabolic stress factors inherent to diabetes, such as chronic hyperglycemia and associated oxidative stress, further exacerbate endothelial vulnerability. Consequently, diabetic patients may experience significantly greater endothelial cell loss during and after cataract surgery, necessitating targeted surgical strategies and careful perioperative management to preserve corneal health and visual outcomes. This paper aims to conduct an extensive and detailed review of the existing scientific literature to thoroughly investigate the relationship between ECL and cataract surgery in patients diagnosed with DM2. This study conducts a critical evaluation to elucidate the mechanisms contributing to high endothelial vulnerability in individuals with diabetes. It systematically compares the rates of ECL observed in diabetic and non-diabetic populations undergoing cataract surgery, examines molecular alterations following the procedure in patients with and without DM2, identifies key risk factors influencing surgical outcomes, evaluates the impact of various surgical techniques, discusses preventative measures, and examines the long-term consequences of ECL in this specific population. Furthermore, this review analyzes the existing research to identify gaps in knowledge and suggest potential directions for future investigations. Full article
(This article belongs to the Special Issue Molecular Research in Ocular Pathology)
►▼ Show Figures

Figure 1

Other

Jump to: Review

19 pages, 1241 KiB  
Systematic Review
Therapeutic Potential of Rho Kinase Inhibitors in Corneal Disease: A Systematic Review of Preclinical and Clinical Studies
by Laura Andreea Ghenciu, Diana Andrei, Claudia Borza, Roxana Iacob, Emil Robert Stoicescu, Sorin Lucian Bolintineanu, Daniela Iacob and Ovidiu Alin Haţegan
Biomedicines 2025, 13(7), 1602; https://doi.org/10.3390/biomedicines13071602 - 30 Jun 2025
Viewed by 638
Abstract
Background/Objectives: Rho-associated coiled-coil-containing protein kinase inhibitors (ROCKis) have now become known as modulators of corneal endothelial wound repair and cell survival. However, evidence remains fragmented across laboratory and clinical reports. We performed a systematic review to synthesize preclinical and clinical data on ROCKis [...] Read more.
Background/Objectives: Rho-associated coiled-coil-containing protein kinase inhibitors (ROCKis) have now become known as modulators of corneal endothelial wound repair and cell survival. However, evidence remains fragmented across laboratory and clinical reports. We performed a systematic review to synthesize preclinical and clinical data on ROCKis in corneal disease, assess their efficacy and safety, and identify research gaps. Methods: We searched PubMed, Web of Science, Scopus, and Google Scholar (until May 2025) for English-language original studies evaluating ROCKis in corneal models or patients. Inclusion criteria encompassed in vitro, ex vivo, in vivo, and clinical trials reporting functional outcomes (endothelial cell density, wound closure, visual acuity). Results: Thirty-one studies met criteria: 14 preclinical studies and 17 clinical studies. Preclinical models (rabbit, porcine, human explants) uniformly showed ROCKis (Y-27632, Ripasudil, Netarsudil, H-1152) accelerate corneal endothelial cell proliferation, migration, and restoration of a hexagonal monolayer with improved barrier and pump function over days to weeks. In 17 clinical investigations, topical Ripasudil or Netarsudil and cultured cell injections achieved significant corneal thinning, endothelial cell density and central corneal thickness changes, and visual acuity improvements (≥2 lines) with minimal adverse events. Overall bias was moderate in non-randomized studies and low in the RCTs. Conclusions: ROCKis demonstrate consistent pro-regenerative effects on corneal endothelium in multiple models and show promising clinical efficacy in Fuchs endothelial dystrophy and pseudophakic endothelial failure. Future work should explore novel delivery systems and larger controlled trials to optimize dosing, safety, and long-term outcomes. Full article
(This article belongs to the Special Issue Molecular Research in Ocular Pathology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop